Human genetic resources such as organs, cells, and tissue are crucial to the clinical trials that pharmaceutical multinationals conduct in order to get their products registered for use in China, whether it be a new drug or medical device.
Podcast #33: Foreign-Sponsored Clinical Trials Under China's Human Genetic Resources Regime – Tina Wu, Haiwen & Partners
China's HGR regime still delays foreign-sponsored clinical research despite recent streamlining of review process
By
Vincent Chow